Janet Helliwell
Nurse Practitioner · Longmeadow, MANPI 1053612309
Payments from drug & device makers
Across 204 payments — averaging $21.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$426
- Lilly USA, LLC$379
- AstraZeneca$336
- Novo Nordisk$312
- Exact Sciences$275
- plus $2K from 17 others
What the payments were for
- Food & beverage$4,12094%
- Education$2446%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 78 | $1,131 |
| Johnson & Johnson | 10 | $426 |
| Lilly USA, LLC | 21 | $379 |
| AstraZeneca | 13 | $336 |
| Novo Nordisk | 12 | $312 |
| Exact Sciences | 11 | $275 |
| Boehringer Ingelheim | 12 | $242 |
| Abbott | 10 | $233 |
| Astellas Pharma US Inc | 3 | $218 |
| Antares Pharma, Inc. | 11 | $205 |
| GSK | 1 | $112 |
| Axsome Therapeutics, Inc. | 3 | $93 |
| Halozyme Inc | 4 | $86 |
| E.r. Squibb & Sons, L.L.C. | 3 | $62 |
| Gilead | 2 | $53 |
| Amgen | 2 | $46 |
| Pfizer | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Merck | 1 | $22 |
| Novartis | 1 | $21 |
| Corium, LLC | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$239
- TRELEGY ELLIPTA$112
- Ozempic$108
How this compares
$4,364 in reported general payments places this provider in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 16 | $24,021 |
| MounjaroTirzepatide | 15 | $18,498 |
| Mirtazapine | 19 | $835 |
| Rosuvastatin Calcium | 21 | $406 |
| Amlodipine Besylate | 80 | $384 |
| Omeprazole | 23 | $316 |
| Levetiracetam | 16 | $292 |
| Montelukast Sodium | 12 | $277 |
| Losartan Potassium | 21 | $247 |
| Metoprolol Succinate | 13 | $234 |
| Bisoprolol Fumarate | 11 | $229 |
| Metformin Hcl | 31 | $226 |
| Atorvastatin Calcium | 25 | $176 |
| Hydrochlorothiazide | 11 | $133 |
| Levothyroxine Sodium | 13 | $132 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $312 | $24,02116 claims |
| Lilly USA, LLCMounjaro | $379 | $18,49815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.
Other nurse practitioner in Longmeadow
- Alison McManusBoston$346K
- Lauri WelchNorth Chelmsford$110K
- Teresa FogarenBoston$102K
- Carolyn MetivierBoston$93K
- Deborah GearySalem$80K
- Amberly ChaplinWorcester$56K
- Darlene MadoreBrockton$42K
- Nancy SydowN Chelmsford$35K
- Miu Lai NgBoston$33K
- Victoria Garcia AlbeaStoneham$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.